Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.

Current cancer drug targets - 1 Jan 2018

Jia Yi-Tao, Yang Dong-Hai, Zhao Zhaolong, Bi Xiao-Hui, Han Wei-Hua, Feng Bo, Zhi Jie, Gu Bin, Duan Zhihui, Wu Jian-Hua, Ju Ying-Chao, Wang Ming-Xia, Li Zhong-Xin

Abstract excerpt

BACKGROUND: It remains unknown whether blockade of c-Met signaling and epidermal growth factor receptor signaling is effective in suppressing the growth of human colorectal cancer (CRC) cells. In this study, we investigated the effects of the c-Met inhibitor PHA-665752 alone and in combination with cetuximab on the growth of human CRC cells in vitro and in mouse xenografts. METHODS: Human CRC cell lines (Caco2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Vitro Techniques

Share to Indoles

Share to Mice, Nude

Share to Proto-Oncogene Proteins p21(ras)

Share to Sulfones

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28359236
DOI: 10.2174/1568009617666170330112841

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.PMID 28359236Read ↗

c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.Semantic proximity Read ↗

Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transitionSemantic proximity Read ↗

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.Semantic proximity Read ↗

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.Semantic proximity Read ↗

Beauvericin Induces Mitochondrial Apoptosis and Attenuates EMT-Associated Phenotypes and Angiogenic Signaling in Colorectal Cancer Cells In Vitro.Semantic proximity Read ↗

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.Semantic proximity Read ↗

Combination effect of cetuximab with radiation in colorectal cancer cells.Semantic proximity Read ↗

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Semantic proximity Read ↗

Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.Semantic proximity Read ↗

γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules.Semantic proximity Read ↗

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Semantic proximity Read ↗

Standard chemotherapy with cetuximab for treatment of colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.